CAS RN: 25316-40-9 | Product Number: D4193
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
|Purity / Analysis Method||>95.0%(HPLC)|
|Molecular Formula / Molecular Weight||C__2__7H__2__9NO__1__1·HCl = 579.98|
|Physical State (20 deg.C)||Solid|
|Condition to Avoid||Light Sensitive,Heat Sensitive|
|Related CAS RN||23214-92-8|
|Reaxys Registry Number||4229251|
|PubChem Substance ID||253660149|
|Merck Index (14)||3439|
|Appearance||Light yellow to Yellow to Orange powder to crystal|
|Purity(HPLC)||min. 95.0 area%|
|Specific rotation [a]20/D||+240 to +270 deg(C=0.1,MeOH)|
|Specific Rotation||248° (C=0.1,MeOH)|
|Maximum Absorption Wavelength||497(H2O) nm|
|Solubility in water||Soluble|
|Solubility (soluble in)||Tetrahydrofuran,Methanol|
|Solubility (insoluble in)||Ether,Benzene,Chloroform,Acetone|
|Hazard Statements||H302 : Harmful if swallowed.
H361 : Suspected of damaging fertility or the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure.
H351 : Suspected of causing cancer.
|Precautionary Statements||P501 : Dispose of contents/ container to an approved waste disposal plant.
P260 : Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events
Adriamycin-induced chronic proteinuria: a structural and functional study
Effect of dietary protein restriction on renal purines and purine-metabolizing enzymes in adriamycin nephrosis in rats: a mechanism for protection against acute proteinuria involving xanthine oxidase inhibition
Effect of enalapril on adriamycin-induced nephrosis
Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats
Protective effects of sinomenine against doxorubicin-induced nephrosis in rats
Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity
Experimental animal models of adriamycin cardiotoxicity
Adriamycin-induced cardiomyopathy. A rat model
Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium
Serial assessment of myocardial properties using cyclic variation of integrated backscatter in an adriamycin-induced cardiomyopathy rat model
Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I
Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure
Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats Longitudinal in vivo study.
The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin
- Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
- The Power and Potential of Doxorubicin-DNA Adducts
- Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Safety Data Sheet (SDS) Search
The requested SDS is not available.
Please check that the Product Number you have entered is correct.
If your information is correct and you are still not able to view the requested SDS, please Contact Us for more information.